Molbio Diagnosti Q1 FY27 Results (NSE: MOLBIO)

· Analysis by Alpha Inflection

Signal: Loss reversed

The read

The main inflection is the return to profitability from a ₹239.44 million consolidated loss and ₹237.14 million owners' loss a year ago, but the -27.2% sequential revenue decline and ₹106.99 million finance cost require confirmation that the recovery is durable rather than a low-base rebound.

Molbio Diagnosti Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹408.38 Cr+309.6%-27.2%
EBIT₹86.61 CrN/A
Net profit₹58.75 CrN/A (prior-year loss)
EPS₹5.21N/A (prior-year loss)
EBIT margin25.4%

P&L walk

Consolidated revenue rose to ₹4,083.76 million from ₹997.08 million, while EBITDA margin was 25.4%; the recovery was helped by lower raw-material intensity, although finance cost rose to ₹106.99 million and non-controlling interest reduced reported group profit to ₹527.44 million versus owners' profit of ₹587.47 million.

Segments

The standalone parent generated ₹3,993.78 million of the ₹4,083.76 million consolidated revenue and ₹566.27 million of standalone profit versus ₹587.47 million attributable to owners, so the consolidated uplift was modest while non-controlling interests reduced total group profit by ₹60.03 million.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.